ArticleBMC cancer2023

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.

Agathe Vienne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.